UniQure Stock Surges 60% on Positive AMT-130 Huntington’s Gene Therapy Data

Jul 9, 2024, 02:51 PM

UniQure has announced positive interim data from its Phase I/II trials of AMT-130, a gene therapy for Huntington’s disease. The data demonstrated a statistically significant, dose-dependent slowing of disease progression, with patients receiving high-dose AMT-130 showing an 80% reduction in the progression of the disease in the composite Unified Huntington’s measure. Following this announcement, uniQure's stock surged by 60%, reflecting investor optimism about the potential of this one-time therapy. The stock saw a pre-market increase of 27% and continued to rise throughout the day.